Elin Miller - Marrone Bio Chairperson, Board of Directors
| MBIIDelisted Stock | USD 0.80 0.00 0.00% |
Director
Ms. Elin D. Miller has resigned as Director of the Company. effective 25 May 2016. Ms. Miller is the Principal of Elin Miller Consulting LLC and she also currently serves on the board of directors of Vestaron Corporation a venturebacked agricultural biotechnology firm. Appointed by the President of the United States Ms. Miller assumed regional management of the U.S. Environmental Protection Agency in the Pacific Northwest from 2006 to 2009. Prior to serving at the EPA Ms. Miller led Arysta Lifescience Corporation as President and Chief Executive Officer of North America and Australasia from 2004 to 2006. Ms. Miller also served in various positions at Dow AgrosciensesDow Chemical from 1996 to 2004 including Vice President of Pest Management Vice President of Asia Pacific and Global Vice President of Public Affairs. Ms. Millers career also includes directing the California Department of Conservation and serving as Chief Deputy Director of the Department of Pesticide Regulation at the California Environmental Protection Agency since 2016.
| Age | 54 |
| Tenure | 8 years |
| Phone | 530 750-2800 |
| Web | www.marronebioinnovations.com |
Marrone Bio Management Efficiency
The company has return on total asset (ROA) of (14.91) % which means that it has lost $14.91 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (71.75) %, meaning that it created substantial loss on money invested by shareholders. Marrone Bio's management efficiency ratios could be used to measure how well Marrone Bio manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 35.46 M in liabilities with Debt to Equity (D/E) ratio of 1.55, which is about average as compared to similar companies. Marrone Bio Innovations has a current ratio of 0.77, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Marrone Bio until it has trouble settling it off, either with new capital or with free cash flow. So, Marrone Bio's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Marrone Bio Innovations sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Marrone to invest in growth at high rates of return. When we think about Marrone Bio's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Timothy Godwin | NETGEAR | 64 | |
| Martha Brooks | Jabil Circuit | 62 | |
| Neil Novich | Analog Devices | 63 | |
| Edward Frank | Analog Devices | 61 | |
| Bradley Maiorino | NETGEAR | 47 | |
| Masahiko Nozaki | Renesas Electronics | 60 | |
| Ann Millner | Merit Medical Systems | 65 | |
| Richard Beyer | Analog Devices | 66 | |
| Lawrence Murphy | Jabil Circuit | 71 | |
| Kent Stanger | Merit Medical Systems | 62 | |
| Jose Almeida | Analog Devices | 52 | |
| Thomas Lawrence | Cumberland Pharmaceuticals | 74 | |
| Anousheh Ansari | Jabil Circuit | 54 | |
| Kelley StevenWaiss | FormFactor | 49 | |
| Lothar Maier | FormFactor | 63 | |
| Michael Zellner | FormFactor | 62 | |
| Nobuyuki Nakano | Renesas Electronics | 56 | |
| Kathleen Walters | Jabil Circuit | 69 | |
| Christopher Genualdi | NETGEAR | N/A | |
| Martin Cearnal | Cumberland Pharmaceuticals | 69 | |
| Thomas Gunderson | Merit Medical Systems | 66 | |
Management Performance
| Return On Equity | -71.75 | |||
| Return On Asset | -14.91 |
Marrone Bio Innovations Leadership Team
Elected by the shareholders, the Marrone Bio's board of directors comprises two types of representatives: Marrone Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Marrone. The board's role is to monitor Marrone Bio's management team and ensure that shareholders' interests are well served. Marrone Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Marrone Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Pamela Contag, Director | ||
| Richard Rominger, Director | ||
| Linda Moore, Chief Compliance Officer, VP, General Counsel and Secretary | ||
| Elin Miller, Chairperson, Board of Directors | ||
| Kathleen Merrigan, Director | ||
| Tim Fogarty, Director | ||
| James Boyd, CFO, VP and Assistant Secretary | ||
| Keith McGovern, Director | ||
| Stuart Woolf, Director | ||
| Timothy Fogarty, Chairperson of the Board | ||
| Phyllis Himmel, Vice President - Research & Development | ||
| Pamela Marrone, Founder, CEO and President and Director | ||
| Shaugn Stanley, Director | ||
| Michael Benoff, Director | ||
| Robert Woods, Chairman of the Board | ||
| Kevin Hammill, Chief Commercial Officer | ||
| Zachary Wochok, Director | ||
| George Kerckhove, Director | ||
| Brian Ahrens, VP of Sales | ||
| Keith Pitts, Vice President of Regulatory and Government Affairs | ||
| Nancy Hood, Vice President - Marketing | ||
| Timothy Johnson, VP of Field Devel. and Technical Services | ||
| Yogesh Mago, Independent Director | ||
| Alison Stewart, Senior Vice President - R&D, Chief Technical Officer | ||
| Amit Vasavada, Vice President - Research and Development |
Marrone Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Marrone Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -71.75 | |||
| Return On Asset | -14.91 | |||
| Profit Margin | (47.08) % | |||
| Operating Margin | (43.72) % | |||
| Current Valuation | 171.62 M | |||
| Shares Outstanding | 180.71 M | |||
| Shares Owned By Insiders | 1.30 % | |||
| Shares Owned By Institutions | 67.62 % | |||
| Number Of Shares Shorted | 1.81 M | |||
| Price To Earning | (0.82) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Other Consideration for investing in Marrone Stock
If you are still planning to invest in Marrone Bio Innovations check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Marrone Bio's history and understand the potential risks before investing.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |